0.606
-0.16 (-21.26%)
| Penutupan Terdahulu | 0.770 |
| Buka | 0.748 |
| Jumlah Dagangan | 28,206,464 |
| Purata Dagangan (3B) | 3,923,957 |
| Modal Pasaran | 16,265,149 |
| Harga / Jualan (P/S) | 0.180 |
| Harga / Buku (P/B) | 0.640 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Jan 2025 |
| Margin Keuntungan | -186.98% |
| Margin Operasi (TTM) | -41.87% |
| EPS Cair (TTM) | -17.51 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 34.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 96.53% |
| Nisbah Semasa (MRQ) | 1.05 |
| Aliran Tunai Operasi (OCF TTM) | -154.64 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -32.56 M |
| Pulangan Atas Aset (ROA TTM) | -33.18% |
| Pulangan Atas Ekuiti (ROE TTM) | -193.76% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | 23andMe Holding Co. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.67 |
|
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 12.22% |
| % Dimiliki oleh Institusi | 24.78% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sapphire Ventures, L.L.C. | 31 Dec 2024 | 264,592 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 26 Mar 2025 | Pengumuman | 23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law |
| 23 Mar 2025 | Pengumuman | 23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process |
| 21 Mar 2025 | Pengumuman | 23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test |
| 03 Mar 2025 | Pengumuman | 23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki |
| 31 Jan 2025 | Pengumuman | 23andMe Launches New Genetic Report on Osteoporosis |
| 28 Jan 2025 | Pengumuman | 23andMe Special Committee Announces Exploration of Strategic Alternatives |
| 28 Jan 2025 | Pengumuman | 23andMe Reports Third Quarter Fiscal Year 2025 Financial Results |
| 08 Jan 2025 | Pengumuman | 23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |